Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Tacrine is a centrally acting acetylcholinesterase inhibitor and indirect cholinergic agonist (parasympathomimetic). It was the first centrally acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney in 1949.…
Applications, Adverse effects & Clinical use
Explore the main themes, entities and connections around Tacrine. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
treatment inhibitor also centrally acting first effects trade name cognex cyp1a2 pdbe liver link conclusively proven acetylcholinesterase cholinesterase alzheimer's disease
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Tacrine | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Tacrine | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Tacrine | ATC code | N06DA01 (WHO) | 1.00 | infobox |
| Tacrine | Bioavailability | 2.4–36% (oral) | 1.00 | infobox |
| Tacrine | Boiling point | 358 °C (676 °F) | 1.00 | infobox |
| Tacrine | CAS Number | 321-64-2 Y | 1.00 | infobox |
| Tacrine | ChEBI | CHEBI:45980 Y | 1.00 | infobox |
| Tacrine | ChEMBL | ChEMBL95 Y | 1.00 | infobox |
| Tacrine | ChemSpider | 1859 Y | 1.00 | infobox |
| Tacrine | CompTox Dashboard (EPA) | DTXSID1037272 | 1.00 | infobox |
| Tacrine | DrugBank | DB00382 Y | 1.00 | infobox |
| Tacrine | ECHA InfoCard | 100.005.721 | 1.00 | infobox |
| Tacrine | Elimination half-life | 2–4 hours | 1.00 | infobox |
| Tacrine | Excretion | Renal | 1.00 | infobox |
| Tacrine | Formula | C13H14N2 | 1.00 | infobox |
| Tacrine | IUPHAR/BPS | 6687 | 1.00 | infobox |
| Tacrine | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Tacrine | Legal status | BR: Class C1 (Other controlled substances) | 1.00 | infobox |
| Tacrine | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Tacrine | Legal status | US: ℞-only | 1.00 | infobox |
| Tacrine | MedlinePlus | a693039 | 1.00 | infobox |
| Tacrine | Melting point | 183 °C (361 °F) | 1.00 | infobox |
| Tacrine | Metabolism | Hepatic (CYP1A2) | 1.00 | infobox |
| Tacrine | Molar mass | 198.269 g·mol−1 | 1.00 | infobox |
| Tacrine | PDB ligand | THA (PDBe, RCSB PDB) | 1.00 | infobox |
| Tacrine | Pregnancy category | AU: C | 1.00 | infobox |
| Tacrine | Protein binding | 55% | 1.00 | infobox |
| Tacrine | Routes of administration | Oral, rectal | 1.00 | infobox |
| Tacrine | Trade names | Cognex | 1.00 | infobox |
| Tacrine | UNII | 4VX7YNB537 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.